GUTIERREZ, ESTHER
GUTIERREZ, ESTHER
Corrigendum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2020;97:1287–1296 (Kidney International (2020) 97(6) (1287–1296), (S0085253820301526), (10.1016/j.kint.2020.01.035))
2021 Rondeau E.; Scully M.; Ariceta G.; Barbour T.; Cataland S.; Heyne N.; Miyakawa Y.; Ortiz S.; Swenson E.; Vallee M.; Yoon S.-S.; Kavanagh D.; Haller H.; Babu S.; Broeders N.; Lietar N.; Brown F.; Campbell P.; Campistol J.M.; Blasco M.; Chowdhury P.; Kasimatis T.; Cirami L.; Caroti L.; Antognoli G.; Delmas Y.; Dobronravov V.; Gaeckler A.; Garrouste C.; Greenwood G.; Griffin S.; Huang C.-C.; Chen I.-R.; Huang S.; Kim J.S.; La Manna G.; Comai G.; Cappuccilli M.; Le Quintrec M.; Jeantet G.; Fumie I.; Luque Y.; Menne J.; Morelle J.; Goffin E.; Muhlfeld A.; Nagaraj S.; Arepally G.; Oh D.; Okumi M.; Terente M.P.; Gutierrez E.; Rodriguez P.; Provot F.; Schonermarck U.; Fischereder M.; Terrada N.R.; Seitz-Polski B.; Favre G.; Boyer-Suavet S.; Vinogradova M.; Kirsanova T.; Wong E.K.S.
Erratum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment” Kidney Int. 2020;97:1287–1296 (Kidney International (2020) 97(6) (1287–1296), (S0085253820301526), (10.1016/j.kint.2020.01.035))
2020 Rondeau E.; Scully M.; Ariceta G.; Barbour T.; Cataland S.; Heyne N.; Miyakawa Y.; Ortiz S.; Swenson E.; Vallee M.; Yoon S.-S.; Kavanagh D.; Haller H.; Babu S.; Broeders N.; Lietar N.; Brown F.; Campbell P.; Chowdhury P.; Kasimatis T.; Cirami L.; Caroti L.; Antognoli G.; Delmas Y.; Dobronravov V.; Gaeckler A.; Garrouste C.; Greenwood G.; Griffin S.; Huang C.-C.; Chen I.-R.; Huang S.; Kim J.S.; La Manna G.; Comai G.; Cappuccilli M.; Le Quintrec M.; Jeantet G.; Fumie I.; Luque Y.; Menne J.; Morelle J.; Goffin E.; Muhlfeld A.; Nagaraj S.; Arepally G.; Oh D.; Okumi M.; Terente M.P.; Gutierrez E.; Rodriguez P.; Provot F.; Schonermarck U.; Fischereder M.; Terrada N.R.; Seitz-Polski B.; Favre G.; Boyer-Suavet S.; Vinogradova M.; Kirsanova T.; Wong E.K.S.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Corrigendum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2020;97:1287–1296 (Kidney International (2020) 97(6) (1287–1296), (S0085253820301526), (10.1016/j.kint.2020.01.035)) | Rondeau E.; Scully M.; Ariceta G.; Barbour T.; Cataland S.; Heyne N.; Miyakawa Y.; Ortiz S.; Swen...son E.; Vallee M.; Yoon S.-S.; Kavanagh D.; Haller H.; Babu S.; Broeders N.; Lietar N.; Brown F.; Campbell P.; Campistol J.M.; Blasco M.; Chowdhury P.; Kasimatis T.; Cirami L.; Caroti L.; Antognoli G.; Delmas Y.; Dobronravov V.; Gaeckler A.; Garrouste C.; Greenwood G.; Griffin S.; Huang C.-C.; Chen I.-R.; Huang S.; Kim J.S.; La Manna G.; Comai G.; Cappuccilli M.; Le Quintrec M.; Jeantet G.; Fumie I.; Luque Y.; Menne J.; Morelle J.; Goffin E.; Muhlfeld A.; Nagaraj S.; Arepally G.; Oh D.; Okumi M.; Terente M.P.; Gutierrez E.; Rodriguez P.; Provot F.; Schonermarck U.; Fischereder M.; Terrada N.R.; Seitz-Polski B.; Favre G.; Boyer-Suavet S.; Vinogradova M.; Kirsanova T.; Wong E.K.S. | 2021-01-01 | KIDNEY INTERNATIONAL | - | 1.04 Replica / breve intervento (e simili) | - |
| Erratum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment” Kidney Int. 2020;97:1287–1296 (Kidney International (2020) 97(6) (1287–1296), (S0085253820301526), (10.1016/j.kint.2020.01.035)) | Rondeau E.; Scully M.; Ariceta G.; Barbour T.; Cataland S.; Heyne N.; Miyakawa Y.; Ortiz S.; Swen...son E.; Vallee M.; Yoon S.-S.; Kavanagh D.; Haller H.; Babu S.; Broeders N.; Lietar N.; Brown F.; Campbell P.; Chowdhury P.; Kasimatis T.; Cirami L.; Caroti L.; Antognoli G.; Delmas Y.; Dobronravov V.; Gaeckler A.; Garrouste C.; Greenwood G.; Griffin S.; Huang C.-C.; Chen I.-R.; Huang S.; Kim J.S.; La Manna G.; Comai G.; Cappuccilli M.; Le Quintrec M.; Jeantet G.; Fumie I.; Luque Y.; Menne J.; Morelle J.; Goffin E.; Muhlfeld A.; Nagaraj S.; Arepally G.; Oh D.; Okumi M.; Terente M.P.; Gutierrez E.; Rodriguez P.; Provot F.; Schonermarck U.; Fischereder M.; Terrada N.R.; Seitz-Polski B.; Favre G.; Boyer-Suavet S.; Vinogradova M.; Kirsanova T.; Wong E.K.S. | 2020-01-01 | KIDNEY INTERNATIONAL | - | 1.04 Replica / breve intervento (e simili) | - |